About FIRAZYR

Put the power of portable treatment in your patient's hands

Katie is a real hereditary angioedema (HAE) patient

Here you'll learn important information about FIRAZYR, the only prefilled, self-administered, subcutaneous injection for acute attacks of HAE in adults 18 years and older.1

Efficacy

FIRAZYR is approved to treat acute HAE attacks, including cutaneous, abdominal and laryngeal.1

See cutaneous and abdominal attack study results »
See laryngeal and multiple attack study results »

FIRAZYR Safety Profile

See warnings and precautions, adverse reactions, drug interactions, and other important information you should know about FIRAZYR.

Review safety profile »

MOA

FIRAZYR inhibits bradykinin from binding to the B2 receptor and thereby treats the clinical symptoms of an acute, episodic attack of HAE.1

Learn about how FIRAZYR works »

Dosing & Administration

Patients may self-administer FIRAZYR upon recognition of symptoms of an HAE attack, after training by a healthcare professional.1

Learn more about dosing and administration »

Encouraging Patient Compliance

Make sure your patients are prepared for their next acute attack as part of an ongoing, on-demand treatment plan.2,3

See tips on facilitating compliance »